HE4 as a predictor of adjuvant chemotherapy resistance and survival in patients with epithelial ovarian cancer

Mona Aarenstrup Karlsen; Claus Høgdall; Lotte Nedergaard; Kira Philipsen Prahm; Nikoline Marie Schou Karlsen; Anne Weng Ekmann-Gade; Tine Henrichsen-Schnack; Tim Svenstrup Poulsen; Ib Jarle Christensen; Estrid Høgdall

doi:10.1111/apm.12625

HE4 as a predictor of adjuvant chemotherapy resistance and survival in patients with epithelial ovarian cancer

Mona Aarenstrup Karlsen, Claus Høgdall, Lotte Nedergaard, Kira Philipsen Prahm, Nikoline Marie Schou Karlsen, Anne Weng Ekmann-Gade, Tine Henrichsen-Schnack, Tim Svenstrup Poulsen, Ib Jarle Christensen, Estrid Høgdall

10 Citations (Scopus)

Abstract

The aim of this study was to investigate the value of serum human epididymis protein 4 (HE4) and HE4 tissue protein expression to predict tumor resistance to adjuvant chemotherapy, progression-free survival (PFS), and overall survival in patients with epithelial ovarian cancer (EOC). Consecutive inclusion of 198 patients diagnosed with EOC was conducted. Blood samples were collected prior to surgery and tissue samples during surgery. Patient data were registered prospectively in the Danish Gynecologic Cancer Database. The association between serum HE4 and HE4 tissue protein expression, resistance to adjuvant chemotherapy, PFS, and overall survival were analyzed in univariate analyses and in multivariate analyses adjusted for age, performance score, surgical outcome, stage, grade, and histological subtype. Serum HE4 levels predicted chemotherapy resistance, PFS, and overall survival correlated significantly (p < 0.001) in the univariate analyses; but after adjustment in a multivariate model, serum HE4 was insignificant, except in a subgroup analysis of postmenopausal women, where serum HE4 significantly predicted resistance to chemotherapy and progression-free survival. HE4 tissue protein expression predicted PFS (p = 0.022) and overall survival (p = 0.047) in the univariate analysis, while HE4 tissue protein expression failed to predict these outcomes in the adjusted multivariate analyses. Serum HE4 or HE4 tissue protein expression are not independent factors of chemotherapy resistance or survival in patients with EOC, but serum HE4 might predict chemotherapy resistance and PFS in postmenopausal women.

Original language	English
Journal	APMIS - Journal of Pathology, Microbiology and Immunology
Volume	124
Issue number	12
Pages (from-to)	1038-1045
Number of pages	8
ISSN	0903-4641
DOIs	https://doi.org/10.1111/apm.12625
Publication status	Published - 1 Dec 2016

Keywords

Adult
Aged
Aged, 80 and over
Antineoplastic Agents
Chemotherapy, Adjuvant
Denmark
Disease Progression
Drug Resistance
Female
Humans
Middle Aged
Neoplasms, Glandular and Epithelial
Ovarian Neoplasms
Ovary
Prognosis
Prospective Studies
Proteins
Serum
Survival Analysis
Treatment Outcome
Journal Article

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/apm.12625

Cite this

Aarenstrup Karlsen, M., Høgdall, C., Nedergaard, L., Prahm, K. P., Schou Karlsen, N. M., Weng Ekmann-Gade, A., Henrichsen-Schnack, T., Poulsen, T. S., Christensen, I. J., & Høgdall, E. (2016). HE4 as a predictor of adjuvant chemotherapy resistance and survival in patients with epithelial ovarian cancer. APMIS - Journal of Pathology, Microbiology and Immunology, 124(12), 1038-1045. https://doi.org/10.1111/apm.12625

HE4 as a predictor of adjuvant chemotherapy resistance and survival in patients with epithelial ovarian cancer. / Aarenstrup Karlsen, Mona; Høgdall, Claus; Nedergaard, Lotte et al.

In: APMIS - Journal of Pathology, Microbiology and Immunology, Vol. 124, No. 12, 01.12.2016, p. 1038-1045.

Research output: Contribution to journal › Journal article › Research › peer-review

Aarenstrup Karlsen, M, Høgdall, C, Nedergaard, L, Prahm, KP, Schou Karlsen, NM, Weng Ekmann-Gade, A, Henrichsen-Schnack, T, Poulsen, TS, Christensen, IJ & Høgdall, E 2016, 'HE4 as a predictor of adjuvant chemotherapy resistance and survival in patients with epithelial ovarian cancer', APMIS - Journal of Pathology, Microbiology and Immunology, vol. 124, no. 12, pp. 1038-1045. https://doi.org/10.1111/apm.12625

@article{7f754b6755d74a15a571267a625045ab,

title = "HE4 as a predictor of adjuvant chemotherapy resistance and survival in patients with epithelial ovarian cancer",

abstract = "The aim of this study was to investigate the value of serum human epididymis protein 4 (HE4) and HE4 tissue protein expression to predict tumor resistance to adjuvant chemotherapy, progression-free survival (PFS), and overall survival in patients with epithelial ovarian cancer (EOC). Consecutive inclusion of 198 patients diagnosed with EOC was conducted. Blood samples were collected prior to surgery and tissue samples during surgery. Patient data were registered prospectively in the Danish Gynecologic Cancer Database. The association between serum HE4 and HE4 tissue protein expression, resistance to adjuvant chemotherapy, PFS, and overall survival were analyzed in univariate analyses and in multivariate analyses adjusted for age, performance score, surgical outcome, stage, grade, and histological subtype. Serum HE4 levels predicted chemotherapy resistance, PFS, and overall survival correlated significantly (p < 0.001) in the univariate analyses; but after adjustment in a multivariate model, serum HE4 was insignificant, except in a subgroup analysis of postmenopausal women, where serum HE4 significantly predicted resistance to chemotherapy and progression-free survival. HE4 tissue protein expression predicted PFS (p = 0.022) and overall survival (p = 0.047) in the univariate analysis, while HE4 tissue protein expression failed to predict these outcomes in the adjusted multivariate analyses. Serum HE4 or HE4 tissue protein expression are not independent factors of chemotherapy resistance or survival in patients with EOC, but serum HE4 might predict chemotherapy resistance and PFS in postmenopausal women.",

keywords = "Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Chemotherapy, Adjuvant, Denmark, Disease Progression, Drug Resistance, Female, Humans, Middle Aged, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Ovary, Prognosis, Prospective Studies, Proteins, Serum, Survival Analysis, Treatment Outcome, Journal Article",

author = "{Aarenstrup Karlsen}, Mona and Claus H{\o}gdall and Lotte Nedergaard and Prahm, {Kira Philipsen} and {Schou Karlsen}, {Nikoline Marie} and {Weng Ekmann-Gade}, Anne and Tine Henrichsen-Schnack and Poulsen, {Tim Svenstrup} and Christensen, {Ib Jarle} and Estrid H{\o}gdall",

note = "{\textcopyright} 2016 APMIS. Published by John Wiley & Sons Ltd.",

year = "2016",

month = dec,

day = "1",

doi = "10.1111/apm.12625",

language = "English",

volume = "124",

pages = "1038--1045",

journal = "APMIS. Supplementum",

issn = "0903-465X",

publisher = "Wiley Online",

number = "12",

}

TY - JOUR

T1 - HE4 as a predictor of adjuvant chemotherapy resistance and survival in patients with epithelial ovarian cancer

AU - Aarenstrup Karlsen, Mona

AU - Høgdall, Claus

AU - Nedergaard, Lotte

AU - Prahm, Kira Philipsen

AU - Schou Karlsen, Nikoline Marie

AU - Weng Ekmann-Gade, Anne

AU - Henrichsen-Schnack, Tine

AU - Poulsen, Tim Svenstrup

AU - Christensen, Ib Jarle

AU - Høgdall, Estrid

PY - 2016/12/1

Y1 - 2016/12/1

N2 - The aim of this study was to investigate the value of serum human epididymis protein 4 (HE4) and HE4 tissue protein expression to predict tumor resistance to adjuvant chemotherapy, progression-free survival (PFS), and overall survival in patients with epithelial ovarian cancer (EOC). Consecutive inclusion of 198 patients diagnosed with EOC was conducted. Blood samples were collected prior to surgery and tissue samples during surgery. Patient data were registered prospectively in the Danish Gynecologic Cancer Database. The association between serum HE4 and HE4 tissue protein expression, resistance to adjuvant chemotherapy, PFS, and overall survival were analyzed in univariate analyses and in multivariate analyses adjusted for age, performance score, surgical outcome, stage, grade, and histological subtype. Serum HE4 levels predicted chemotherapy resistance, PFS, and overall survival correlated significantly (p < 0.001) in the univariate analyses; but after adjustment in a multivariate model, serum HE4 was insignificant, except in a subgroup analysis of postmenopausal women, where serum HE4 significantly predicted resistance to chemotherapy and progression-free survival. HE4 tissue protein expression predicted PFS (p = 0.022) and overall survival (p = 0.047) in the univariate analysis, while HE4 tissue protein expression failed to predict these outcomes in the adjusted multivariate analyses. Serum HE4 or HE4 tissue protein expression are not independent factors of chemotherapy resistance or survival in patients with EOC, but serum HE4 might predict chemotherapy resistance and PFS in postmenopausal women.

AB - The aim of this study was to investigate the value of serum human epididymis protein 4 (HE4) and HE4 tissue protein expression to predict tumor resistance to adjuvant chemotherapy, progression-free survival (PFS), and overall survival in patients with epithelial ovarian cancer (EOC). Consecutive inclusion of 198 patients diagnosed with EOC was conducted. Blood samples were collected prior to surgery and tissue samples during surgery. Patient data were registered prospectively in the Danish Gynecologic Cancer Database. The association between serum HE4 and HE4 tissue protein expression, resistance to adjuvant chemotherapy, PFS, and overall survival were analyzed in univariate analyses and in multivariate analyses adjusted for age, performance score, surgical outcome, stage, grade, and histological subtype. Serum HE4 levels predicted chemotherapy resistance, PFS, and overall survival correlated significantly (p < 0.001) in the univariate analyses; but after adjustment in a multivariate model, serum HE4 was insignificant, except in a subgroup analysis of postmenopausal women, where serum HE4 significantly predicted resistance to chemotherapy and progression-free survival. HE4 tissue protein expression predicted PFS (p = 0.022) and overall survival (p = 0.047) in the univariate analysis, while HE4 tissue protein expression failed to predict these outcomes in the adjusted multivariate analyses. Serum HE4 or HE4 tissue protein expression are not independent factors of chemotherapy resistance or survival in patients with EOC, but serum HE4 might predict chemotherapy resistance and PFS in postmenopausal women.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Antineoplastic Agents

KW - Chemotherapy, Adjuvant

KW - Denmark

KW - Disease Progression

KW - Drug Resistance

KW - Female

KW - Humans

KW - Middle Aged

KW - Neoplasms, Glandular and Epithelial

KW - Ovarian Neoplasms

KW - Ovary

KW - Prognosis

KW - Prospective Studies

KW - Proteins

KW - Serum

KW - Survival Analysis

KW - Treatment Outcome

KW - Journal Article

U2 - 10.1111/apm.12625

DO - 10.1111/apm.12625

M3 - Journal article

C2 - 27859687

SN - 0903-465X

VL - 124

SP - 1038

EP - 1045

JO - APMIS. Supplementum

JF - APMIS. Supplementum

IS - 12

ER -

HE4 as a predictor of adjuvant chemotherapy resistance and survival in patients with epithelial ovarian cancer

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this